Apomorphine pharmacokinetic-pharmacodynamic correlations following single and repeated subcutaneous injections in patients with Parkinson's disease

被引：0
|
作者：
Bottini, PB
Shaw, A
Huang, MY
Sherry, JH
机构：
来源：
MOVEMENT DISORDERS | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P293
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [41] Response of tremor to subcutaneous apomorphine in patients with tremor predominant idiopathic Parkinson's disease
    Hellmann, M
    Sabach, T
    Melamed, E
    Djaldetti, R
    MOVEMENT DISORDERS, 2004, 19 : S147 - S147
  • [42] Pharmacokinetic-pharmacodynamic relationship of marbofloxacin for Escherichia coli and Pasturella multocida following repeated intramuscular administration in goats
    Bhardwaj, Pallavi
    Sidhu, Pritam K.
    Saini, Simrat Pal Singh
    Dinesh, M. B.
    Rampal, Satyavan
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2019, 42 (04) : 430 - 439
  • [43] Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
    Peter Hagell
    Arja Höglund
    Carina Hellqvist
    Eva-Lena Johansson
    Berit Löwed
    Anne-Christine Sjöström
    Carina Karlberg
    Margareth Lundgren
    Nil Dizdar
    Anders Johansson
    Thomas Willows
    Johan Rådberg
    Filip Bergquist
    Journal of Neurology, 2020, 267 : 3411 - 3417
  • [44] Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
    Hagell, Peter
    Hoglund, Arja
    Hellqvist, Carina
    Johansson, Eva-Lena
    Lowed, Berit
    Sjostrom, Anne-Christine
    Karlberg, Carina
    Lundgren, Margareth
    Dizdar, Nil
    Johansson, Anders
    Willows, Thomas
    Radberg, Johan
    Bergquist, Filip
    JOURNAL OF NEUROLOGY, 2020, 267 (11) : 3411 - 3417
  • [45] A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis
    Mould, DR
    Davis, CB
    Minthorn, EA
    Kwok, DC
    Elliott, MJ
    Luggen, ME
    Totoritis, MC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) : 246 - 257
  • [46] Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease
    Wang, Z.
    Gomeni, R.
    Pahwa, R.
    Hauser, R.
    Formella, A.
    Grall, M.
    Upadhyaya, H.
    Rubin, J.
    MOVEMENT DISORDERS, 2024, 39 : S390 - S391
  • [47] Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease
    Mueller, Thomas
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (10) : 1423 - 1432
  • [48] Pharmacodynamic and Pharmacokinetic Features of CabergolineRationale for Use in Parkinson’s Disease
    R. G. Fariello
    Drugs, 1998, 55 : 10 - 16
  • [49] Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease.
    Drapier, S.
    Verin, M.
    REVUE NEUROLOGIQUE, 2006, 162 (10) : 1019 - 1023
  • [50] Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease
    Garcia Ruiz, Pedro J.
    MOVEMENT DISORDERS, 2006, 21 (05) : 727 - 728
12345